CD38 and acute myeloid leukemia: In this preclinical setting, we further demonstrated that a low dose of chidamide can sensitize conventional chemotherapeutics to leukemia stem cell-like cells, including CD34+CD38− KG1α cells, CD34+CD38− Kasumi cells, and primary AML stem/progenitor cells.